ArticleClinical, cosmetic and investigational dermatology2025
Comorbidity Pattern in Patients with Moderate-to-Severe Plaque Psoriasis: Network Analysis of a Hospitalized Database in China.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Biological Therapy Leads to a Reduction in Systemic Inflammation but Leaves Serum Uric Acid Unmodified in Moderate-to-Severe Plaque Psoriasis: A Prospective Longitudinal Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Psoriasis is a chronic systemic inflammatory disorder characterized by a high prevalence of comorbid conditions, profoundly affecting patient quality of life and complicating treatment strategies. This study aims to analyze demographic characteristics, prevalence, age distribution, and gender differences of psoriatic comorbidities in hospitalized patients with moderate-to-severe psoriasis at a single center. Additionally, we explore the correlation between comorbidities and psoriasis through network analysis. Methods: A retrospective cross-sectional study was conducted using electronic medical records from the Shanghai Skin Disease Hospital, spanning 2021 to 2023. After removing duplicates, 506 patients diagnosed with plaque psoriasis were included. Comprehensive data on demographics, medical histories, laboratory indices, and comorbid conditions were collected. The Phenotypic Comorbidity Network (PCN) method was employed to examine coexistence patterns of psoriasis with various diseases. Results: 79.64% of patients had at least one comorbidity, with Non-alcoholic Fatty Liver Disease (NAFLD), hypertension, hyperlipidemia, overweight/obesity, and hyperuricemia being the top five common comorbidities. The prevalence of these comorbidities increased substantially in the 30-40 and 50-70 age cohorts, notably in hepatic dysfunction and metabolic syndrome. Male patients showed a slightly higher propensity for comorbidities compared to females. Early-onset psoriasis (EOP) patients showed a higher risk for specific conditions than late-onset psoriasis (LOP) patients. PCN analysis identified hepatic dysfunction, hypertension, metabolic syndrome, NAFLD, obesity, hyperlipidemia, and diabetes as strongly associated with psoriasis. Conclusion: This study underscores the systemic nature of psoriasis and its association with diverse comorbidities, emphasizing the necessity of a holistic management approach that addresses both dermatological and comorbid conditions. Identifying key comorbidities guides clinicians in implementing targeted screening and preventive strategies, enhancing patient care and potentially alleviating the overall disease burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.